Preventing Device Infections In Dialysis Patients

Cardiac implantable electronic devices (CIEDs) have transformed the management of bradyarrhythmia, heart failure, and sudden cardiac death. Pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronisation systems can provide substantial survival and quality-of-life benefits. For people receiving haemodialysis, however, implantation and long-term device care occur within a particularly complex clinical setting.

Dialysis patients have a higher risk of bloodstream infection because of repeated vascular access, frequent healthcare contact, immune dysfunction, diabetes, older age, and exposure to invasive procedures. A device pocket infection or lead-associated endocarditis can therefore become a serious and resource-intensive complication. Infection may require complete system extraction, prolonged antimicrobial therapy, temporary pacing, and a carefully timed reimplantation strategy.

The clinical balance is especially important in Australia, where renal and electrophysiology services span major tertiary hospitals in Sydney, Melbourne, Brisbane, Perth, Adelaide, and regional centres with more limited procedural capacity. Patients may travel long distances for device implantation or extraction, while dialysis schedules, vascular access preservation, and local antimicrobial protocols must all be coordinated.

Prevention begins before the procedure and continues throughout the life of the device. A tailored approach should combine infection control, vascular-access planning, careful patient selection, early recognition of symptoms, and multidisciplinary follow-up. Outcomes depend on how quickly infection is identified, whether the entire system is removed when indicated, and how safely a new device can be provided.

Why Dialysis Increases Infection Risk

End-stage kidney disease is associated with impaired innate and adaptive immune responses. Uraemia, malnutrition, diabetes, anaemia, and repeated exposure to hospital environments can reduce resistance to bacterial invasion. Haemodialysis adds frequent cannulation and manipulation of an arteriovenous fistula, graft, or central venous catheter, creating repeated opportunities for transient or sustained bacteraemia.

Central venous dialysis catheters carry the greatest risk of bloodstream infection. Staphylococcus aureus, coagulase-negative staphylococci, and other skin flora are frequent pathogens in CIED infection, although Gram-negative organisms and polymicrobial infections may occur. A bacteraemic episode can seed the device pocket, leads, valves, or endocardium, even when the implantation wound initially healed normally.

The interaction between a CIED and dialysis access also matters mechanically. Transvenous leads may contribute to central venous stenosis, which can compromise future fistula creation or cause arm and breast swelling. A dialysis catheter placed on the same side as an existing device may further complicate venous drainage and infection management. Early communication between nephrology, vascular access teams, and electrophysiology is therefore essential.

Assessing Device Need Before Implantation

The best infection prevention strategy is to implant a device only when its expected benefit clearly outweighs procedural risk. Indication should be reviewed against contemporary pacing and defibrillator guidance, the patient’s prognosis, functional status, comorbidities, and goals of care. In advanced kidney disease, competing mortality risks can influence whether a defibrillator or cardiac resynchronisation system is likely to provide meaningful benefit.

Before implantation, clinicians should document any active infection, recent bacteraemia, fever, skin lesion, dental infection requiring treatment, or suspected vascular-access infection. Elective procedures should generally be delayed until infection has been treated and the patient is clinically stable. Recent bloodstream infection deserves particular caution, with repeat cultures and targeted investigation when clinically indicated.

The choice of system can also affect future risk. A transvenous device may be unsuitable when central venous access is severely limited or when infection risk is exceptionally high. Selected patients may be considered for a subcutaneous ICD, leadless pacemaker, or alternative pacing configuration, although each option has specific limitations, eligibility criteria, costs, and follow-up requirements. These decisions should be individualised rather than driven by device type alone.

Australian hospitals also work within Therapeutic Goods Administration requirements and local procurement arrangements. Availability of leadless systems, antibacterial envelopes, extraction equipment, and specialist operators can differ between metropolitan and regional services. A documented referral pathway is particularly important when a patient from rural New South Wales, Western Australia, or Queensland may need transfer to a tertiary extraction centre.

Peri-Procedural Infection Prevention

Standard precautions remain central: appropriate hand hygiene, skin antisepsis, sterile draping, a properly prepared theatre or procedure room, and minimisation of unnecessary staff traffic. Intravenous antimicrobial prophylaxis should be selected according to local epidemiology, allergy status, renal function, and institutional policy. Dialysis timing may influence antibiotic dosing and should be planned with the renal team.

Pre-procedure management should include attention to glycaemic control, nutrition, anaemia, anticoagulation, and skin integrity. The dialysis access must be protected, and blood pressure measurement or venepuncture should be avoided in an arm containing a functioning fistula unless clinically necessary. If a temporary dialysis catheter is present, its infection status and planned removal should be considered before implantation.

For patients at particularly high risk, an antibacterial envelope may be considered during implantation or revision. Evidence supports selective use in populations with elevated infection risk, but the decision should account for local device availability, antimicrobial stewardship, allergic reactions, cost, and the absolute benefit expected for the individual. Australian public and private hospitals may have different procurement pathways, so the option should be discussed early rather than assumed to be routinely available.

Pocket haematoma is a significant modifiable risk factor. Careful haemostasis, thoughtful management of antiplatelet and anticoagulant medicines, and avoidance of unnecessary reintervention can reduce the likelihood of haematoma and secondary infection. A swollen, painful, or oozing pocket after discharge warrants prompt assessment rather than repeated outpatient dressing changes without specialist review.

Care After Implantation

The wound should be reviewed according to local practice, with clear instructions about redness, drainage, wound separation, increasing tenderness, fever, chills, or unexplained malaise. Patients receiving dialysis may initially attribute fatigue or temperature changes to their usual treatment, so education should explain that new systemic symptoms can signal infection even when the pocket looks normal.

Dialysis units are well placed to identify early warning signs because staff see patients regularly. They should inspect the device site when clinically appropriate, record episodes of bacteraemia, and communicate promptly with the implanting service. A shared plan can specify whom to contact after hours, how blood cultures should be obtained, and when hospital transfer is required.

Long-term prevention includes maintaining high standards for vascular-access care. Arteriovenous fistulas generally have lower infection risk than central venous catheters, so catheter avoidance and timely fistula planning remain important. Patients should also be advised to inform dentists, surgeons, emergency clinicians, and dialysis staff that they have an implanted device, while avoiding blanket antibiotic use for procedures where prophylaxis is not indicated.

Education needs to be culturally safe and practical. For Aboriginal and Torres Strait Islander patients, care should involve Aboriginal health workers or liaison services where available, support family participation, and account for travel, housing, language, and continuity-of-care barriers. The same principles apply to people living far from metropolitan hospitals, where telehealth, shared-care arrangements, and transport coordination can prevent delayed review.

Recognising And Investigating Infection

CIED infection may present as a pocket abscess, erosion, sinus tract, unexplained wound inflammation, persistent fever, recurrent bacteraemia, or infective endocarditis. Some patients have minimal local findings. Staphylococcus aureus bacteraemia in a person with a pacemaker or ICD should prompt active consideration of device involvement, even when another possible source is identified.

Evaluation commonly includes multiple blood cultures before antibiotics when the patient is stable, laboratory assessment, device and pocket examination, and echocardiography. Transthoracic echocardiography may be followed by transoesophageal echocardiography when lead infection or endocarditis remains possible. Advanced imaging can support diagnosis in selected cases, but results must be interpreted alongside clinical findings and microbiology.

Antibiotics alone are often insufficient when an established CIED infection involves the pocket or intravascular hardware. Suppressive therapy may be considered only in exceptional circumstances when extraction is impossible or carries prohibitive risk. Infectious diseases, nephrology, electrophysiology, cardiac surgery, and the dialysis team should agree on antimicrobial selection and dosing, including adjustments for dialysis clearance.

Contemporary evidence and specialist guidance can be followed through the Journal of Arrhythmia collections, where themed material on electrophysiology, devices, ablation, and related clinical practice supports continuing professional education.

Extraction And Reimplantation Decisions

When definite CIED infection is present, complete removal of the generator and leads is usually required. Delaying extraction can permit persistent bacteraemia, embolic complications, relapse, and progressive endocarditis. Lead extraction in dialysis patients may be technically demanding because of venous occlusion, calcification, long lead dwell time, frailty, and limited access for a replacement system.

The procedure should be performed by an experienced multidisciplinary team with appropriate surgical backup and a plan for vascular access and dialysis. The timing of extraction depends on haemodynamic stability, organism, extent of infection, embolic risk, and response to antimicrobial therapy. Haemodialysis access must be protected throughout the admission, and temporary pacing may be necessary for pacemaker-dependent patients.

Reimplantation should occur only after infection is controlled and blood cultures have cleared according to the treating team’s assessment. The new system should generally use a different route or configuration when feasible. A contralateral transvenous approach may be limited by central venous disease, while leadless pacing or a subcutaneous ICD may offer alternatives for selected patients. The choice must account for pacing requirements, defibrillation indications, dialysis access, anatomy, and expected longevity.

Outcomes are influenced by prompt diagnosis, complete hardware removal, pathogen-directed therapy, and coordinated follow-up. Persistent infection, renal failure, advanced age, heart failure, and repeated procedures increase mortality risk, but dialysis should not automatically exclude patients from definitive treatment when the device remains clinically necessary.

Building A Reliable Care Pathway

A written pathway can reduce delays between dialysis units, emergency departments, infectious diseases services, and electrophysiology teams. It should include contact details, criteria for urgent referral, blood-culture procedures, antimicrobial dosing responsibilities, transport arrangements, and documentation of device type and indication. A device identification card and accessible electronic record are valuable when patients attend multiple hospitals.

Quality improvement should track pocket infections, bloodstream infections after implantation, reinterventions, extraction outcomes, readmissions, and time from suspected infection to specialist assessment. Reviewing cases can reveal preventable contributors such as peri-procedural haematoma, delayed culture collection, inadequate communication, or missed vascular-access planning.

Research and clinical practice continue to evolve around antibacterial envelopes, leadless pacing, subcutaneous defibrillators, remote monitoring, and extraction techniques. Clinicians can access peer-reviewed research and educational material through the Journal of Arrhythmia, the official publication of leading heart rhythm societies in the Asia-Pacific region.

A practical Australian model links metropolitan electrophysiology expertise with local dialysis services. Shared protocols can support patients in outer Melbourne, regional Queensland, or remote Western Australia without requiring every follow-up visit to occur in a tertiary hospital. The goal is a consistent safety net: prevent avoidable infection, identify danger signs early, and provide rapid access to definitive care.

Clinicians caring for dialysis patients with pacemakers, ICDs, or resynchronisation devices should review local protocols, establish direct referral contacts, and discuss device infection prevention at multidisciplinary renal and rhythm meetings. Early planning with patients and families can preserve dialysis access, shorten delays, and improve the chance of a safe long-term outcome.